REG - AstraZeneca PLC - Alexion completes Pfizer gene therapy agreement

AstraZenecaAnnouncement

20/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230920:nRST9762Ma&default-theme=true

RNS Number : 9762M  AstraZeneca PLC  20 September 2023

20 September 2023

Alexion completes purchase and licence agreement for early-stage rare disease
gene therapy portfolio from Pfizer

Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and
licence agreement
(https://www.astrazeneca.com/media-centre/press-releases/2023/alexion-enters-gene-therapy-agreement-with-pfizer.html)
for a portfolio of preclinical rare disease gene therapy programmes and
enabling technologies from Pfizer Inc. (Pfizer).

 

These new resources build on the combined capabilities of Alexion and
AstraZeneca in genomic medicine, with the objective to develop new genetic
therapies with improved safety and efficacy profiles. Additionally, several of
the Pfizer employees associated with the portfolio will join Alexion as
employees.

 

Financial considerations

Alexion has purchased and licenced the assets of Pfizer's early-stage rare
disease gene therapy portfolio for a total consideration of up to $1bn, plus
tiered royalties on sales.

Notes

 

Alexion

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on
rare diseases, created following the 2021 acquisition of Alexion
Pharmaceuticals, Inc. As a leader in rare diseases for nearly 30 years,
Alexion is focused on serving patients and families affected by rare diseases
and devastating conditions through the discovery, development and
commercialisation of life-changing medicines. Alexion focuses its research
efforts on novel molecules and targets in the complement cascade and its
development efforts on haematology, nephrology, neurology, metabolic
disorders, cardiology and ophthalmology. Headquartered in Boston,
Massachusetts, Alexion has offices around the globe and serves patients in
more than 50 countries.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the
Company on social media @AstraZeneca
(https://www.linkedin.com/company/astrazeneca/) .

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFWFMUEDSEDU